News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theradiag Obtains CE Mark for Proprietary Anti-CCP IVD Kit



4/23/2013 7:14:46 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CROISSY-BEAUBOURG, France--(BUSINESS WIRE)--

Regulatory News:

Theradiag (ALTER.PA) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for its proprietary anti-CCP in vitro diagnostic (IVD) kit in rheumatoid arthritis. This test further expands the Fidis portfolio of diagnostic tests for auto-immunes diseases, which significantly decreases costs and time of analysis thanks to the Multiplex technology. Fidis is the most complete multiplex range of diagnostics currently marketed.

This new way of detecting anti cyclic citrullinated peptides (anti-CCPs) antibodies allows for highly-reliable detection of severe forms of RA through a more rapid dosing and at a lower cost than existing tests.

"This new CE mark shows our ability to further expand our high-value IVD portfolio. With this new addition to the Fidis range, we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases. This anti-CCP test strengthens our in house products portfolio, in line with our development strategy. The new kits will be available internationally, like all our other Fidis products" commented Michel Finance, CEO of Theradiag.

The new anti-CCP test is the third proprietary diagnostic kit of Theradiag to obtain a CE mark this year. The auto-immune diseases segment grew strongly in 2012 (+17% for Fidis products), making-up for 43 percent of company sales in 2012.

About Theradiag

Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Contact:

Theradiag

Investor Relations

Nathalie Trepo, Tél: 01 64 62 10 12

ntrepo@theradiag.com

or

NewCap.

Financial Communications

and investor relations

Valentine Brouchot / Pierre Laurent, Tél. : 01 44 71 98 52

theradiag@newcap.fr

or

Alize RP

Press

Caroline Carmagnol, Tél. : 06 64 18 99 59

caroline@alizerp.com

or

Christian Berg, Tél. : 01 42 68 86 41

christian@alizerp.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Theradiag
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES